Best practice in primary care pathology: Review 13

Journal of Clinical Pathology

Volumn 65, Issue 2, 2012, Pages 97-100

  Cabrera Abreu, J C ^a   Smellie, W S A ^b   Bowley, R ^c   Shaw, N ^c  

^a ROYAL BERKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^b BISHOP AUCKLAND GENERAL HOSPITAL   (United Kingdom)

^c Bede House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CA 27-29 ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; DISEASE SEVERITY; EMBASE; EVIDENCE BASED MEDICINE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; IMMUNOASSAY; MASS SCREENING; MEDLINE; NEOPLASM; PRIMARY HEALTH CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY;

CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EARLY DETECTION OF CANCER; HUMANS; MUCIN-1; NEOPLASMS; PRIMARY HEALTH CARE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84856109382     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200292     Document Type: Review

References (37)

1. Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ 2009:339:852-8.
2. Smellie WS, Forth J, Sundar S, et al. Best practice in primary care pathology. Review 4. J Clin Pathol 2006;59:893-902. (Pubitemid 44422840)
3. Perkins G, Slater E, Sanders G, et al. Serum tumor markers. Am Fam Physician 2003;68:1075-82. (Pubitemid 37173829)
4. Association of Clinical Biochemists in Ireland. Guidelines for the Use of Tumour Markers. 3rd edn. 2005. http://acbi.ie (accessed 29 Jun 2011).
5. Smellie WSA, Bowley R, Shaw N, et al. Best practice in primary care pathology. Review 8. J Clin Pathol 2007;60:740-8. (Pubitemid 47056901)
6. European Group on Tumour Markers. Tumour Markers in Gastrointestinal Cancers. EGTM Recommendations. 2007. http://egtm.eu (accessed 29 Jun 2011).
7. Eche N, Pichon MF, Quillien V, et al. Groupe de travail Nicole Eche (coordonnateur), oncobiologiste. Standards, options and recommendations for tumour markers in colorectal cancer. Bull Cancer 2001;88:1177-206.
8. Begent RH. The value of carcinoembryonic antigen measurement in clinical practice. Ann Clin Biochem 1984;21:231-8. (Pubitemid 14093372)
9. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:1-26.
10. European Group on Tumour Markers. Tumour Markers in Breast Cancer. EGTN Recommendations. 2007. http://egtm.eu (accessed 29 Jun 2011).
11. Royal College of Pathologists of Australasia. RCPA. Pathology Tests. Carcinoembryonic Antigen. 2004. http://rcpamanual.edu.au (accessed 29 Jun 2011).
12. SIGN Guideline 67. Management of Colorectal Cancer. 2003. http://www.sign.ac. uk/guidelines/fulltext/67/index.html (accessed 29 Jun 2011).
13. Miles W, Greig J, Seth J, et al. Raised carcinoembryonic antigen level as an indicator of recurrent disease in follow up of patients with colorectal cancer. Br J Gen Pract 1995;45:287-8.
14. McArdle C. ABC of colorectal cancer: effectiveness of follow up. BMJ 2000;321:1332-5.
15. Tiandra JJ, Chan MK. Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 2007;50:1783-99. (Pubitemid 350077100)
16. Improving Outcomes in Colorectal Cancer Manual Updates. NICE, 2004. http:// guidance.nice.org.uk/CSGCC/Guidance/pdf/English (accessed 29 Jun 2011).
17. FACS trial. http://www.facs.soton.ac.uk (accessed 29 Jun 2011).
18. Guadagni F, Ferroni P, Carlini S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001;7:2357-62. (Pubitemid 32751636)
19. Maestranzi S, Przemioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998;35:99-103. (Pubitemid 28043632)
20. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5. (Pubitemid 20140602)
21. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998;35:364-70. (Pubitemid 28230734)
22. Charatcharoenwitthaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008;48:1106-17.
23. Tanaka N, Okada S, Ueno H, et al. The usefulness of serial changes in serum Ca 19- 9 levels in the diagnosis of pancreatic cancer. Pancreas 2000;20:378-81. (Pubitemid 30253650)
24. Nouts A, Levy P, Voitot H, et al. Diagnostic value of serum CA 19-9 antigen in chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterol Clin Biol 1988;22:152-9.
25. Glen J, Steinberg WM, Kurtzman SH, et al. Evaluation of the utility of radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6:462-8. (Pubitemid 18090693)
26. Beretta E, Malesci A, Zerbi A, et al. Serum CA 19-9 in the post-surgical follow-up of patients with pancreatic cancer. Cancer 1987;60:7428-31.
27. Staab HJ, Brummendorf A, Hornung A, et al. The clinical validity of circulating tumour-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies. Klin Wochenschr.1985;63:106-15. (Pubitemid 15163712)
28. Filella X, Molina R, Pique JM, et al. Use of CA19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumor Biol 1994;18:1-6. (Pubitemid 24122938)
29. Basuyau JP, Blanc-Vincent MP, Bidart JM, et al. Standards, options and recommendations (SOR) for tumour markers in breast cancer. SOR Working Group. Bull Cancer 2000;87:723-37.
30. Duffy MJ. Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 2006;52:345-51.
31. Martin A, Corte MD, Alvarez AM, et al. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res 2006;26:3965-71. (Pubitemid 44701484)
32. Ebeling FG, Stieber P, Untch M, et al. Serum CEA and CA 15-3 as prognostic factors in primary breast cancer. Br J Cancer 2002;86:1217-22.
33. Smellie WS, Vanderpump MP, Fraser WD, et al. Best practice in primary care pathology. Review 11. J Clin Pathol 2008;61:410-18. (Pubitemid 351518220)
34. Smellie WS, McNulty CA, Collinson PO, et al. Best practice in primary care pathology. Review 12. J Clin Pathol 2010;63:330-6.
35. Smellie WS, Wilson D, Finnegan DI, et al. Best practice in pathology. Methodology for constructing guidance. J Clin Path 2005;58:249-53. (Pubitemid 40380317)
36. General Medical Services Contract. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-116299 (accessed 29 Jun 2011).
37. NHS Confederation. Quality and Outcomes Framework. Guidance for GMS Contract 2009/10. NHS Confederation. http://www.nhsemployers.org/ PayAndContracts/ GeneralMedicalServicescontract/qof/Pages/ QualityOutcomesFramework.aspx (accessed 29 Jun 2011).